 |
Propylamines - Adverse effects
Research News and Information
Sunday, November 22, 2009
30 Aug 2009 
Attention Deficit Hyperactivity Disorder (ADHD) is not only a childhood disorder but symptoms persist into adolescence and adulthood in approximately one third of the patients. Especially inattention and poor concentration impair driving performance ... Read more...
30 Aug 2009 Attention-deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioural disorders in children. It has been shown that as many as 85% of patients with ADHD have at least one psychiatric co-morbidity, and approximately 60% have at ... Read more...
30 Aug 2009 OBJECTIVES: To examine the efficacy and tolerability of atomoxetine (ATX) in improving cognitive performance of patients with Alzheimer dementia. DESIGN: A randomized, double-blind, placebo (PLA)-controlled, parallel-groups study, starting with a ... Read more...
Latest indexed articles for 'Propylamines - Adverse effects'
These are the very latest articles for this heading:
- [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD] 30 Aug 2009
- Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. 30 Aug 2009
- Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. 30 Aug 2009
- Second opinions improve ADHD prescribing in a medicaid-insured community population. 29 Jun 2009
- Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation.
30 May 2009 - Is suicidality serious? 29 Apr 2009
- A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. 5 Apr 2009
- Two recent updates for psychiatric conditions. 30 Mar 2009
- Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. 30 Mar 2009
- Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. 27 Feb 2009
- Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. 30 Jan 2009
- Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. 28 Jan 2009
- Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. 18 Jan 2009
- Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. 14 Jan 2009
- Attention deficit hyperactivity disorder in prison. 30 Dec 2008
- Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. 30 Dec 2008
- Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder. 30 Dec 2008
- Successful medication withdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessive-compulsive disorder. 30 Dec 2008
- [Raynaud phenomenon as adverse effect of ADHD treatment] 29 Nov 2008
- Acute suicidality after commencing atomoxetine. 29 Sep 2008
See a longer list of these articles.
Technical information about 'Propylamines'
Registry Number: 0
Descriptor UI: D011437
Alternative terms: Propylamines;
Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;
Tree Number: D02.092.831;
History Note: 66